Elon Musk has announced that Neuralink's second product, called Blindsight, is awaiting regulatory approval, with the stated goal of letting people who have never seen experience vision.
Neuralink · Regulatory review
Blindsight moves toward approval, aiming at vision for people who have never seen
Elon Musk says Neuralink's second product, Blindsight, is awaiting regulatory approval. The stated goal is to give vision to people who have never been able to see. No regulator, decision date, or clinical dataset has been confirmed independently.
Where Blindsight sits on the path to clinical use
Stage 1
Laboratory work
Early research and development
→
Stage 2
Early-stage trials
Safety and feasibility work
→
Current claim
Regulatory review
Announced, not independently confirmed
→
Stage 4
Approval and use
Required before routine care
What has been stated
Blindsight is next after Neuralink's first implant product.
The aim is vision for people who have never been able to see.
The claim comes from Musk, the company's leader.
What is not yet known
Which regulator is reviewing the device, and when a decision is due.
What clinical evidence has been submitted.
How much visual detail the device could provide.
Key takeaway
For now, Blindsight is an announced approval process, not a confirmed clinical product.
Regulator confirmation
Supporting evidence
Testing and documentation
Continue reading The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in ✓ Signed in — this article isn’t included in your current plan.Unlocking the full article...